<DOC>
	<DOCNO>NCT01572012</DOCNO>
	<brief_summary>This randomize , open-label Phase 1 pharmacokinetic , tolerability , safety study ondansetron Hylenex give subcutaneously compare ondansetron give intravenously , intramuscularly , orally normal healthy volunteer .</brief_summary>
	<brief_title>Phase 1 Safety , Tolerability PK Study Ondansetron Hylenex Recombinant Healthy Volunteers</brief_title>
	<detailed_description>This randomize , open label , 4 way crossover Phase 1 study pharmacokinetics , safety tolerability 4 mg dose ondansetron administer subcutaneously Hylenex recombinant compare 4 mg dos ondansetron administer intravenously intramuscularly 8 mg dose ondansetron administer orally .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Male female volunteer 1965 year old Females must nonlactating nonpregnant ( negative serum pregnancy test screen ) agree practice effective birth control least 30 day study completion Nonsmoker tobacco/nicotine use previous 6 month Intact normal skin without obscure tattoo , pigmentation lesion Adequate venous access upper extremity Normal vital sign , ECG , lab assess Investigator NCS Serum hemoglobin within site 's normal range Negative drug alcohol screen Able make decision comply study requirement History drug alcohol abuse positive drug alcohol screen Abdominal surgery within last 30 day Phenylketonuria Tobacco nicotine use within previous 6 month Hypersensitivity contraindication ondansetron 5HT3 receptor agonist Received ondansetron within 4 day prior Day 1 Known allergy hyaluronidase ingredient Hylenex recombinant Lower extremity edema Creatinine clearance &lt; 60 mL/min Dehydration ( Grade 2 high ) Hypersensitivity contraindication heparin Abnormal ECG clinically significant QT prolongation history Female pregnant breastfeed Participation clinical trial ( drug device ) within 30 day enrollment Clinically significant medical history , major systemic disease , intercurrent illness , physical examination finding , clinical laboratory test result risk subject 's safety interfere interpretation study result Not able comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>tolerability</keyword>
</DOC>